“Refractory chronic cough can be a debilitating condition that impacts a patient’s everyday life. With limited therapy options available, there is a significant need for new treatments that reduce cough, improve a patient’s quality of life and are well tolerated. P2X3 antagonists, an emerging new class of therapy for refractory chronic cough, have shown promise in addressing the burden of this condition on patients,” commented
Oral Presentation Details:
Title: Improvements in cough severity and cough-related quality of life in a phase 2 trial with the P2X3 antagonist BLU-5937 in refractory chronic cough
Session: Clinical trials in airway diseases: novel treatments and new evidence
Format: Pre-recorded presentation and live QA
For more information and to access the pre-recorded presentation, please visit the ERS congress platform. Following the conference, the presentation materials will be available in the “Scientific Publications” section of
BLU-5937, a highly selective P2X3 antagonist, is in development for RCC, chronic pruritus and other hypersensitization-related disorders.
The P2X3 receptor, which is implicated in cough reflex hypersensitization, is a rational target for treating chronic cough, and it has been evaluated in multiple clinical trials with different P2X3 antagonists. The Company believes that its highly selective P2X3 antagonist has the potential to reduce coughing in patients with RCC, while limiting taste disturbance adverse events.
In addition to RCC and chronic pruritus, the mechanism of BLU-5937 may also have broad therapeutic applicability across other afferent hypersensitization-related disorders, enabling the Company to consider BLU-5937 as a potential treatment for a number of other indications. Consequently,
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in
Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations, the
Chief Financial Officer